You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 12, March 26, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •eTable
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Genetic Disorders
 •Genetics, Other
 •Prostate Disease
 •Oncology
 •Breast Cancer
 •Prostate Cancer
 •Otolaryngology/ Head & Neck Surgery
 •Neoplasms of Head & Neck
 •Alert me on articles by topic

Frequency of Germline Genomic Homozygosity Associated With Cancer Cases

Guillaume Assié, MD, PhD; Thomas LaFramboise, PhD; Petra Platzer, PhD; Charis Eng, MD, PhD

JAMA. 2008;299(12):1437-1445.

Context  Cancer is a multigenic disease resulting from both germline susceptibility and somatic events. While studying loss of heterozygosity (LOH) in cancer tissues, we anecdotally observed a low frequency of heterozygosity in cancer patients compared with controls, raising the question whether homozygosity could play a role in cancer predisposition.

Objectives  To determine the frequency of germline homozygosity in a large series of patients with 3 different types of solid tumors compared with population-based controls.

Design, Setting, and Patients  Germline and corresponding tumor DNA isolated from 385 patients with carcinomas (147 breast, 116 prostate, and 122 head and neck carcinomas) were subjected to whole genome (345-microsatellite marker) LOH analysis.

Main Outcome Measures  Frequency of homozygosity at microsatellite markers in cancer cases vs controls and frequency of somatic LOH in cancers at loci with the highest homozygosity.

Results  We identified 16 loci in common among the 3 cancer types, with significantly increased germline homozygosity frequencies in the cancer patients compared with controls (P < .001). In the cases who happened to be germline heterozygous at these 16 loci, we found a mean (SD) LOH frequency of 58% (4.2%) compared with 50% (7.5%) at 197 markers without increased germline homozygosity (P < .001). Across the genome, this relationship holds as well (r = 0.46; 95% confidence interval, 0.37-0.53; P < .001). We validated the association of specific loci with high germline homozygosity frequencies in an independent, single-nucleotide polymorphism–based, public data set of 205 lung carcinomas from white individuals (P < .05 to P < .001) as well as the correlation between genome-wide germline homozygosity and LOH frequencies (r = 0.21; 95% confidence interval, 0.18-0.24; P < .001).

Conclusions  In our study of 4 different types of solid tumors (our data for 3 types validated in a fourth type), increased germline homozygosity occurred at specific loci. When the germline was heterozygous at these loci, high frequencies of LOH/allelic imbalance occurred at these loci in the corresponding carcinomas.


Author Affiliations: Genomic Medicine Institute (Drs Assié, LaFramboise, Platzer, and Eng), Lerner Research Institute (Drs Assié, Platzer, and Eng), and Taussig Cancer Institute (Dr Eng), Cleveland Clinic Foundation, Cleveland, Ohio; Department of Genetics (Drs LaFramboise and Eng) and Case Comprehensive Cancer Center (Dr Eng), Case Western Reserve University School of Medicine, Cleveland.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

All you need to read in the other general journals
BMJ 2008;336:744-745.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.